Alpha 2.0
Login Register
» Authors » Vivian Go

Vivian Go

Explore the profile of Vivian Go including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 327
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Public Health
Top 10 Co-Authors
William C Miller
Bradley N Gaynes
Brian W Pence
Mina C Hosseinipour
Lindsay Y Dhanani
Christopher F Akiba
Berkeley Franz
Michael Udedi
Tran Viet Ha
Anna Kutengule
Published In
J Int AIDS Soc
AIDS Behav
BMC Psychiatry
J Subst Use Addict Treat
Int J Ment Health Syst
Affiliations
Soon will be listed here.
Recent Articles
1.
Barriers and potential solutions for effective integration of depression care into non-communicable diseases clinics in Malawi: a qualitative end-point evaluation of the SHARP randomized controlled trial
Zimba C, Malava J, Mbota M, Matewere M, Akello H, Akiba C, et al.
Int J Ment Health Syst . 2025 Mar; 19(1):8. PMID: 40050899
Background: The sub-Saharan African Regional Partnership for mental health and capacity building (SHARP) study was a clinic-randomized trial of two implementation strategies for integrating depression screening and treatment into non-communicable...
2.
Mechanisms of resilience and coping to intersectional HIV prevention and drug-use stigma among people who inject drugs in rural Appalachian Ohio
Endres-Dighe S, Sucaldito A, McDowell R, Wright A, LoVette A, Miller W, et al.
Harm Reduct J . 2025 Feb; 22(1):18. PMID: 39972510
Background: Intersectional stigma of drug-use and HIV hinders provision and utilization of HIV prevention services for people who inject drugs (PWID), particularly within rural US communities. Resilience and coping may...
3.
Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing
Dhanani L, Miller W, Go V, Simon J, Franz B
J Subst Use Addict Treat . 2025 Jan; 171:209623. PMID: 39864555
Introduction: Buprenorphine is a highly effective medication for opioid use disorder (MOUD; OUD), which can be prescribed alongside naloxone in the primary care setting as part of a harm reduction...
4.
Different forms of stigma and rural primary care professionals' willingness to prescribe buprenorphine
Franz B, Dhanani L, Bogart S, Fenstemaker C, Miller W, Hall O, et al.
J Subst Use Addict Treat . 2025 Jan; 171:209633. PMID: 39864554
Introduction: Buprenorphine and other medications for opioid use disorder (MOUD) are highly effective but substantially under prescribed in the rural United States. Among the most cited barriers to buprenorphine prescribing...
5.
The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care
Fenstemaker C, Abrams E, King K, Obringer B, Brook D, Go V, et al.
J Gen Intern Med . 2024 Dec; PMID: 39668316
Background: Rural communities have been significantly affected by opioid use disorder (OUD) and related harms but have less access to evidence-based medications for opioid use disorder (MOUD), such as buprenorphine....
6.
Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States
Rutstein S, Lopez C, Davy-Mendez T, Agarwal H, Huffstetler H, Perhac A, et al.
Int J STD AIDS . 2024 Oct; 36(1):47-55. PMID: 39361721
Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) extends dosing intervals from daily to every 8 weeks. Equitable implementation requires anticipating and addressing barriers to use. We described LAI-CAB/RPV eligibility and initiation among...
7.
Knowledge of medications for opioid use disorder and associated stigma among primary care professionals
Piscalko H, Dhanani L, Brook D, Hall O, Miller W, Go V, et al.
Ann Med . 2024 Sep; 56(1):2399316. PMID: 39234650
Background: Medications for opioid use disorder (MOUD) are the gold standard. However, significant barriers limit their use in the primary care setting, including limited knowledge of the medications and stigmatizing...
8.
The War on Drugs, Racialized Capitalism, and Health Care Utilization Among White People Who Use Drugs in 22 Rural Appalachian Counties
Cooper H, Livingston M, Crawford N, Feinberg J, Ford C, Go V, et al.
Am J Public Health . 2024 Sep; 114(10):1086-1096. PMID: 39231413
To analyze War on Drugs encounters and their relationships to health care utilization among White people who use drugs (PWUD) in 22 Appalachian rural counties in Kentucky, West Virginia, Ohio,...
9.
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study
Psaros C, Goodman G, Lee J, Rice W, Kelley C, Oyedele T, et al.
J Int AIDS Soc . 2024 May; 27(5):e26252. PMID: 38783534
Introduction: HPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex...
10.
Positive contact and empathy as predictors of primary care providers' willingness to prescribe medications for opioid use disorder
Dhanani L, Miller W, Hall O, Brook D, Simon J, Go V, et al.
SSM Ment Health . 2024 Apr; 4. PMID: 38558957
Introduction: Patients with opioid use disorder (OUD) have a heightened need for quality health care, including access to evidence-based medications to reduce cravings and prevent overdose. However, primary care providers...